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This Journal section presents a real, challenging case involving a multidrug-resistant organism. The case authors present the rationale for
their therapeutic strategy and discuss the impact of mechanisms of resistance on clinical outcome. An expert clinician then provides a com-
mentary on the case.
Carbapenem-resistant Enterobacteriaceae (CRE) usually infect patients with significant comorbidities and health care exposures.
We present a case of a pregnant woman who developed community-acquired pyelonephritis caused by KPC-producing Kleb-
siella pneumoniae. Despite antibiotic treatment, she experienced spontaneous prolonged rupture of membranes, with eventual
delivery of a healthy infant. This report demonstrates the challenge that CRE may pose to the effective treatment of common
infections in obstetric patients, with potentially harmful consequences to maternal and neonatal health.
Pyelonephritis in pregnancy confers a high risk of maternalcomplications and preterm birth (1). Carbapenem-resistant
Enterobacteriaceae (CRE) threaten patients throughout the con-
tinuum of health care but do not commonly cause community-
associated infections. Extensive resistance and the limited efficacy
of existing alternatives limit the treatment of infections caused by
CRE (2). We review a case of pyelonephritis caused by CRE ac-
quired in the community by an unexpected host, a pregnant
woman, which led to obstetric complications and therapeutic
challenges.
CASE PRESENTATION
A 27-year-old woman (G3P0020) presented at 18 weeks of preg-
nancy to the emergency department of a metropolitan hospital in
northeastern Ohio with fever, rigors, nausea, vomiting, dysuria,
and flank pain. She had a history of recurrent urinary tract infec-
tions (UTIs) since childhood. The most recent episode occurred at
the onset of pregnancy (8 weeks), was caused by Escherichia coli
susceptible to ampicillin and all tested cephalosporins, and was
treated with cephalexin. Previously, she had been prescribed ni-
trofurantoin and trimethoprim-sulfamethoxazole to treat a UTI
caused by similarly susceptible bacteria. She had not traveled out-
side the region and had not been admitted to the hospital in the
past 2 years. Recently, the patient had cared for her mother, who
received chemotherapy for breast and ovarian cancer; the mother
had not been treated at a long-term-care facility.
On admission, the patient’s temperature was 102.4°F, her pulse
was 110 beats/min, and her blood pressure was within the normal
range. On physical examination, dry mucous membranes were
noted; pulmonary auscultation did not reveal any rales, and her
abdomen was gravid and nontender, with a fetal heart rate mea-
sured at 140 beats/min. Right costovertebral angle tenderness was
demonstrated. Urine analysis showed pyuria; empirical antibiotic
treatment with ceftriaxone was administered at 2 g intravenously
(i.v.) every 24 h for 3 days. The patient’s fever persisted, and a
urine culture eventually yielded 100,000 CFU/ml of Klebsiella
pneumoniae. Antimicrobial susceptibility testing (AST) demon-
strated resistance to all beta-lactams, including carbapenems, as
well as aminoglycosides and quinolones (Table 1). Blood cultures
remained sterile, and ultrasound imaging did not reveal abscess or
anatomical anomalies of the urinary tract.
CHALLENGE QUESTION
Which antimicrobial(s) would be appropriate for the patient pre-
sented in the case?
A. Colistin (i.v.)
B. Oral fosfomycin
C. Oral fosfomycin and extended-infusion meropenem
D. Oral fosfomycin and extended-infusion cefepime
E. Ceftazidime-avibactam (i.v.)
F. Meropenem and ertapenem (i.v.)
TREATMENT AND OUTCOME
After the results of AST became available, antimicrobial therapy
was administered; it consisted of one dose of meropenem (2 g
Citation Khatri A, Naeger Murphy N, Wiest P, Osborn M, Garber K, Hecker M,
Hurless K, Rudin SD, Jacobs MR, Kalayjian RC, Salata RA, van Duin D, Perez F,
Bonomo RA, Paterson DL (Commentator), Harris PNA (Commentator). 2015.
Community-acquired pyelonephritis in pregnancy caused by KPC-producing
Klebsiella pneumoniae. Antimicrob Agents Chemother 59:4375– 4378.
doi:10.1128/AAC.00553-15.
Address correspondence to Federico Perez (case author), federico.perez@va.gov;
Robert A. Bonomo (case author), robert.bonomo@va.gov; or
David L. Paterson (commentator), d.paterson1@uq.edu.au.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.00553-15
CHALLENGING CLINICAL CASE IN ANTIMICROBIAL RESISTANCE
August 2015 Volume 59 Number 8 aac.asm.org 4375Antimicrobial Agents and Chemotherapy
standard infusion), followed by two doses of meropenem (2 g i.v.
over 3 h every 8 h), and fosfomycin (3 g per os [p.o.] every 72 h for
a total of three doses). Meropenem was switched to cefepime (6 g
i.v. administered over 24 h by continuous infusion for 6 days).
Urine cultures at days 4 and 12 were sterile.
At week 26 of pregnancy, the patient relapsed with fever, rigors,
and costovertebral angle tenderness. K. pneumoniae with antibi-
otic susceptibilities identical to those of the first organism was
isolated from the urine. The patient again received fosfomycin at 3
g p.o. (one dose) and cefepime at 6 g i.v. over 24 h by continuous
infusion for 14 days, followed by cefepime at 2 g i.v. every 8 h by
standard infusion administered for approximately 10 weeks until
delivery. Urine cultures obtained every week or every other week
remained sterile. At week 38, the patient experienced spontaneous
prolonged rupture of membranes and arrest of labor, leading to
cesarean section with delivery of a healthy infant. During labor,
she received four doses of cefepime at 2 g i.v. every 8 h by standard
infusion. Microbiological cure and resolution of symptoms were
documented at a follow-up visit 6 weeks after delivery (at which
time she was off antibiotics). The infant remained healthy during
the same period.
As this was an unexpected pathogen, we sought to characterize
the strain and its mechanism of resistance to carbapenems and
searched for the presence of blaIMP, blaKPC, blaNDM, and blaVIM.
The blaKPC gene was detected and sequenced as blaKPC-2 (2). Mul-
tilocus sequence typing (MLST), following the method of Dian-
court et al., demonstrated that the KPC-2-harboring K. pneu-
moniae isolate from this case belonged to sequence type 258
(ST258), which is the predominant strain of CRE found in north-
eastern Ohio (2, 3). Further genetic typing using repetitive-se-
quence-based PCR (rep-PCR) revealed that the KPC-2-harboring
K. pneumoniae from this patient shares 80% similarity with
other K. pneumoniae ST258 isolates from northeastern Ohio and
represents a strain that was distinct from the two predominant
clades found in the region (Fig. 1). Additionally, PCR amplifica-
tion and sequencing of the wzi gene of the capsular polysaccharide
cps cluster (according to the method described by Brisse et al. [4])
identified sequence 83, which predicts capsular type K23. In con-
trast, the two predominant KPC-producing K. pneumoniae ST258
clades in northeastern Ohio belong to wzi sequences 29 and 81,
which predict capsular types K41 and K81, respectively.
Here we present a case of complicated urinary tract infection
(cUTI) caused by KPC-producing K. pneumoniae in a pregnant
woman without recent health care exposures or travel history; this
is a very unexpected host for this pathogen. This report highlights
the potential emergence of CRE in community-associated infec-
tions and echoes reports of New Delhi metallo-beta-lactamase
(NDM)-producing Enterobacteriaceae causing cystitis among
community dwellers (5). Molecular typing revealed that the KPC-
producing K. pneumoniae isolate from this case, although belong-
ing to the widespread ST258, is of a genotype and capsular type
different from those of other isolates found in northeastern Ohio.
Therefore, this represents the introduction of a novel strain with
an unusual clinical behavior in our community. The establish-
ment in our region of a network for the molecular surveillance of
CRE allowed us to detect this sentinel event (2). To our knowl-
edge, no other community-acquired CRE infections have oc-
curred in our region.
Infection with KPC-producing K. pneumoniae in this case
proved difficult to treat due to extensive drug resistance and the
potential adverse impact of antibiotics on fetal health. We chose
fosfomycin as the “backbone” of the antibiotic regimen because of
its effectiveness against KPC-producing K. pneumoniae and its
safety when given for bacteriuria in pregnancy (category B) (6, 7).
We refrained from using colistin, a mainstay of therapy against
CRE infection, because the existing evidence is inadequate to de-
termine the risk of fetal harm when polymyxins are used in preg-
nancy (category C), and we would have used this agent only if the
maternal condition had justified the potential risk to the fetus.
Tigecycline was not considered since it may cause fetal harm (cat-
egory D); furthermore, tigecycline has limited effectiveness in the
treatment of UTIs. Rather, we added cefepime, which is regarded
as safe in pregnancy (category B) and offers potential synergistic
TABLE 1 Antimicrobial susceptibility testing of KPC-2-producing K.
pneumoniaea













a According to guidelines issued by the Clinical and Laboratory Standards Institute.
FIG 1 Genetic typing of Klebsiella pneumoniae from the present case with rep-PCR and sequencing of wzi demonstrate that the KPC-2-harboring K. pneumoniae
ST258 isolate from this case differs from the two KPC-2- and KPC-3-producing K. pneumoniae ST258 isolates representative (973/1902 and 677/1607) of the two
clades that predominate in northeastern Ohio.
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activity with fosfomycin, also an inhibitor of cell wall synthesis (8).
Cefepime, a zwitterion, achieves high concentrations in the
periplasm and is a relatively poor substrate for hydrolysis by
KPC-2 beta-lactamase (9). Since cefepime is stable over time, it is
feasible to administer it in continuous infusion in order to maxi-
mize the time that the concentration of the drug exceeds the MIC
of the organism, the most relevant pharmacodynamic parameter.
By using 6 g/day as a continuous infusion, we estimate that levels
in plasma of 20 to 30 g/ml were maintained; moreover, cefepime
achieves a very high concentration in the urine, averaging 3,120
g/ml after the administration of a 2-g dose. We therefore rea-
soned that concentrations of cefepime sufficient to inhibit the
growth of K. pneumoniae (MIC  32 g/ml) would be maintained
in the urine and genitourinary tract. Given that its half-life is 2 h
(in subjects with normal renal function), we estimate that the
concentration of cefepime in urine 2 days after stopping treat-
ment is negligible at 0.00002 g/ml (http://www.accessdata.fda
.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf). In this case,
treatment was prolonged for several weeks until delivery with the
intent of preventing further relapses of pyelonephritis and sepsis,
considered seriously detrimental to the fetus and justifying the
risk of “collateral damage” from antibiotics. This approach was
successful, as proven by sterile urine cultures (obtained weekly
while the patient was on cefepime and 6 weeks after the end of
therapy) and the absence of symptoms.
Meropenem (also category B) administered as a prolonged in-
fusion in combination with fosfomycin may have achieved a
similar effect. Indeed, meropenem administered by continuous
infusion was used successfully to treat a KPC-producing K. pneu-
moniae bloodstream infection arising from a urinary source. In
that case, fresh solutions of meropenem had to be prepared every
8 h to overcome the potential instability of meropenem after sev-
eral hours at room temperature, posing an additional logistical
challenge (10). This, and our limited experience with the use of
carbapenems in pregnancy (relative to that with cephalosporins),
justified the choice of cefepime over meropenem or dual-carbap-
enem therapy.
Ceftazidime coformulated with avibactam, a novel beta-lacta-
mase inhibitor that inactivates KPC, recently received approval by the
U.S. FDA for the treatment of cUTI but was not available when this
patient was treated. Registration trials included one female patient
with cUTI proven to be caused by KPC-producing K. pneumoniae
(meropenem MIC, 8 g/ml) who was successfully treated with
ceftazidime-avibactam. Of note, female patients recruited in these
trials had a negative serum pregnancy test; reproductive toxicol-
ogy studies performed with avibactam during early pregnancy in




In conclusion, this case illustrates an attempt to devise an an-
tibiotic regimen to overcome a molecularly defined mechanism of
resistance that is a challenge to clinicians worldwide. At the same
time, it underscores the obstacles for the delivery of precise and
effective treatment for infections in the era of extensively drug-
resistant organisms, such as genetic heterogeneity of bacteria, host
factors that affect treatment response and recurrence, and limited
knowledge regarding drug combinations.
COMMENTARY
The development of an antibiotic regimen for any given patient is
no easy matter. In the accompanying paper, Khatri and colleagues
describe their decision-making when posed with a pregnant pa-
tient who developed pyelonephritis due to KPC-producing Kleb-
siella pneumoniae. Three issues became relevant when deliberating
on the drug regimen: (i) extensive drug resistance, (ii) the type and
site of the infection (pyelonephritis), and (iii) pregnancy. We will
examine each of these sequentially.
The term “extensive drug resistance” (XDR) refers to loss of
susceptibility to all but one or two antibiotic classes. Although
Khatri and colleagues do not list susceptibility to all antibiotics
which comprise the XDR definition (11), it is clear that KPC pro-
duction severely compromised the antibiotic choice for this pa-
tient. A number of observational studies have suggested that com-
bination antibiotic therapy leads to a superior clinical outcome in
patients with severe infections due to KPC producers than mono-
therapy does (12). It is important to point out that the superiority
of combination antibiotic therapy for KPC producers has not yet
been shown in randomized controlled trials, although such trials
are under way.
Interestingly, Khatri and colleagues chose to use cefepime in
their antibiotic regimen, despite in vitro testing indicating a MIC
of 32 mg/liter, which is defined as “resistant” using current break-
points. A number of authors have now used prolonged infusions
of beta-lactam antibiotics to optimize pharmacodynamic param-
eters and potentially achieve prolonged antibiotic concentrations
above the MIC (13), even if such a MIC may be defined as “resis-
tant.” In this era of XDR, breakpoints should be regarded as
“guidelines” rather than as absolute determinants of the efficacy of
an antibiotic regimen against any given organism.
Increasingly, concentrations of beta-lactam antibiotics can be
measured in clinical practice to determine whether such concen-
trations actually exceed the MIC for a considerable part of the
dosing interval. In a study of 384 critically ill patients receiving
beta-lactams who had drug concentrations measured (14), 16%
did not achieve a target of 50% fTMIC (free antibiotic concen-
trations above the MIC at 50% of the dosing interval), and these
patients were 32% less likely to have a positive clinical outcome. A
positive clinical outcome was associated with increasing 50%
fTMIC and 100% fTMIC ratios (14). This underscores the
importance of infectious disease clinicians interacting with clini-
cal pathologists at their hospitals in order to facilitate introduction
of beta-lactam drug concentrations into routine clinical practice.
The site of infection is also an important consideration in
choosing an antibiotic regimen. The issue of utility of orally ad-
ministered fosfomycin for infections other than cystitis is vexed.
Current guidelines for the treatment of pyelonephritis do not in-
clude fosfomycin as a recommended agent (15). Serum and renal
tissue concentrations of fosfomycin, when administered orally,
are substantially lower than urinary concentrations (16). In one
study, clinical cure of patients with pyelonephritis due to fosfo-
mycin-susceptible E. coli was only 44% in patients treated with
oral fosfomycin (8 g twice daily for 1 week) (16). These results
send a clear message to drug developers – there is an urgent need
for new orally administered antibiotics active against multidrug-
resistant (MDR) and XDR Gram-negative organisms. While the
situation is being improved somewhat with intravenous therapy,
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few new options exist for orally administered therapy (with the
possible exception of eravacycline).
The final consideration in the case presented by Khatri and
colleagues is that of the use of antibiotics in pregnancy. It is esti-
mated that between 19 and 44% of women are prescribed antibi-
otics during pregnancy (17). In the case of critically ill patients,
concerns about the pregnant woman’s well-being typically out-
weigh the potential risk of teratogenicity. However, in most clin-
ical situations, such as the one described, the pregnant state sub-
stantially reduces treatment options. Increasing antibiotic
resistance and the need for classes other than “safe” penicillins and
cephalosporins mandate exploration of the safety in pregnancy of
the antibiotics most likely to be used for XDR organisms.
This case highlights the alarming prospect of a community-
acquired XDR K. pneumoniae infection in an otherwise healthy
host. Unfortunately, it is likely that clinicians will increasingly face
such therapeutic dilemmas in the future.
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